In addition, a multicenter phase II study supported the efficacy and safety of immunotherapy, including 13-cis-retinoic acid and interleukin 2 in locally advanced pancreatic cancer patients [55]. This evidence concerns the gene IL2 and familial pancreatic carcinoma.